Robotic surgery can decrease blood loss and patient pain, lead to a shorter recovery time than a traditional laparoscopic approach, and offers surgeons a shorter learning curve.
Douglas Dahl, MD
Douglas Dahl, MD
Chief, Division of Urologic Oncology
Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers
Departments, Centers, & Programs:
Department of Urology
55 Fruit Street
Boston, MA 02114-2696
165 Cambridge St
Boston, MA 02114
- MD, Yale University School of Medicine
- Residency, Brigham and Women's Hospital
- Fellowship, Dana-Farber Cancer Institute
American Board Certifications
- Urology, American Board of Urology
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Dahl's current research focus is in two areas: novel techniques and technologies for minimally invasive Urologic surgery and clinical trials in Urologic oncology. He developed techniques in laparoscopic radical prostatectomy and laparoscopic partial nephrectomy that are now in clinical use. He has published novel techniques in renal transplant and renal surgery, laparoscopic radical prostatectomy, and laparoscopic hernia repair, and has overseen the design and engineering of devices for improving laparoscopic surgery. He has worked with several of the major equipment makers in developing and testing new equipment for minimally invasive surgery.
Dr. Dahl's current area of oncology research interest is in clinical trials in multimodality treatment of urologic malignancies. He served as an investigator for several national studies in treatment of bladder cancer, salvage surgery for radio-resistant prostate cancer, and a prostate cancer prevention trial. He served on the Human Subjects Committee charged with review and approval of all clinical investigations. His current role at Harvard and the Massachusetts General Hospital, includes serving as the co-Principal Investigator of one of five sections of the Harvard SPORE grant studying renal cell carcinoma serum and tissue markers. He is the national Urology chair for two national studies under the auspices of the RTOG (Radiation Therapy Oncology Group).
- Transperitoneal laparoscopic radical prostatectomy in patients after laparoscopic prosthetic mesh inguinal herniorrhaphy. Brown JA, Dahl DM. Urology. 2004 Feb;63(2):380-2.
- Laparoscopic radical prostatectomy and body mass index: an assessment of 151 sequential cases. Brown JA, Rodin DM, Lee B, Dahl DM. J Urol. 2005 Feb;173(2):442-5.
- Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Stott SL,et al, Dahl DM, Wu CL,et al Sci Transl Med. 2010 Mar 31;2(25):25ra23.
- A prospective study of symptom distress and return to baseline function after open versus laparoscopic radical prostatectomy. Dahl DM, Barry MJ, McGovern FJ, Chang Y, Walker-Corkery E, McDougal WS.J Urol. 2009 Sep;182(3):956-65. Epub 2009 Jul 17.
- Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, et al.M.Clin Imaging. 2009 Jul-Aug;33(4):301-5.
- Laparoscopic inguinal hernia repair during laparoscopic radical prostatectomy. Lee BC, Rodin DM, Shah KK, Dahl DM. BJU Int. 2007 Mar;99(3):637-9.
- The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary? Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS, Zietman AL. BJU Int. 2009 Jul;104(2):179-83. Epub 2008 Dec 23.
- Aug | 14 | 2017
About one in seven men will be affected by prostate cancer in their lifetime. Massachusetts General Hospital urologists share updates on prostate cancer screening and treatments.